Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Filter By:

Search by Keyword (disease, investigator, treatment name):

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Multiple Myeloma

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.

Disease Sites: Multiple Myeloma

Phase: I

Investigator: Dholaria, Bhagirathbhai

NCTID: NCT04108195

Protocol No: VICCHEMP1995

Learn More